Skip to content

13F-HR filed by Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 28 holding rows worth $750,140,000.

Accession
0001855655-22-000011
Filed
2022-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2022

A holdings report, 28 entries on the cover page, a total value of $750,140,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $750,139,000 with VALUE read as thousands by filing date, 13F file number 028-21950. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
GLOBAL BLOOD THERAPEUTICS USD37890U108COM1,175,879$80,077,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM850,385$59,391,000thousands by filing date
INCYTE CORP COM45337C102Stock773,082$51,518,000thousands by filing date
ASCENDIS PHARMA A/S DKK 1.0 AD04351P101SPONSORED ADR497,347$51,356,000thousands by filing date
LEGEND BIOTECH CORP52490G102SPONSORED ADS1,076,591$43,925,000thousands by filing date
BIOGEN INC COM09062X103Stock154,605$41,280,000thousands by filing date
BIOGEN INC COM09062X103Stock150,000$40,050,000thousands by filing datecall
IMMUNOCORE HLDGS PLC ADS45258D105ADR773,079$36,288,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM1,636,211$33,559,000thousands by filing date
ARGENX SE SPONSORED ADR04016X101ADR90,297$31,879,000thousands by filing date
UNITED THERAPEUTICS CORP DEL COM91307C102Stock140,561$29,431,000thousands by filing date
AKERO THERAPEUTICS INC00973Y108COM833,265$28,373,000thousands by filing date
BICYCLE THERAPEUTICS PLC-ADR088786108SPONSORED ADS1,158,686$26,951,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM1,085,142$26,076,000thousands by filing date
AXSOME THERAPEUTICS INC. COM05464T104Stock520,080$23,206,000thousands by filing date
HORIZON THERAPEUTICS PLCG46188101SHS351,405$21,748,000thousands by filing date
ALPINE IMMUNE SCIENCES INC02083G100COM2,214,722$15,946,000thousands by filing date
PROTHENA CORP PLC SHSG72800108Stock235,826$14,298,000thousands by filing date
ARVINAS INC04335A105COM283,777$12,625,000thousands by filing date
ESPERION THERAPEUTICS INC NEW COM29664W105Stock1,719,831$11,523,000thousands by filing date
MERUS N VN5749R100COM564,214$11,301,000thousands by filing date
G1 THERAPEUTICS INC3621LQ109COM884,574$11,048,000thousands by filing date
CRINETICS PHARMACEUTICALS INC COM22663K107Stock519,256$10,198,000thousands by filing date
OYSTER POINT PHARMA INC69242L106COMMON STOCK1,648,316$9,264,000thousands by filing date
TG THERAPEUTICS INC COM88322Q108Stock1,505,479$8,912,000thousands by filing date
POSEIDA THERAPEUTICS INC73730P108COM2,070,108$7,307,000thousands by filing date
VOR BIOPHARMA INC929033108COM1,703,645$6,781,000thousands by filing date
Milestone Pharmaceuticals Inc59935V107COM634,211$5,828,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001855655-22-000011this filing2022-11-14acceptance time not in the bulk data set